Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1988-05-27
1992-03-17
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 26, 514171, 514544, 514709, 514730, A61K 31235, A61K 3156, A61K 3157, A61K 31725
Patent
active
050968920
ABSTRACT:
Anigiogenesis is controlled by administering to a mammal an effective amount of an inhibitor of arylsulfatase. Preferably, the arylsulfatase inhibitor is administered in a pharmaceutically acceptable vehicle in combination with an angiostatic steroid and (optionally) heparin (by which term we include all forms and fragments of heparin having the desired angiostatic activity). Hydrocortisone is one specifically preferred steroid. The preferred arylsulfatase inhibitor is a carboxylic acid ester or a sulfuric acid ester of a benzylic alcohol, most preferably the esters defined more particularly below. The arylsulfatase inhibitor is preferably administered locally to the tissue experiencing undesired angiogenesis. Arylsulfatase inhibitor and an angiostatic steroid are included in a pharmaceutically acceptable vehicle, preferably also with heparin, to yield an angiostatic thereapeutic composition. Also, coagulation of blood is inhibited by adding a composition comprising an arylsulfatase inhibitor and heparin to the blood. Such compositions are also disclosed.
REFERENCES:
patent: 4460368 (1984-07-01), Allison et al.
patent: 4771042 (1988-09-01), Braughler et al.
patent: 4788307 (1988-11-01), Lormeau et al.
Smith et al; Biochem. Pharmacol., 25:2171-2177 (1976).
The Merck Index; Ed. M. Windholz, pp. 4538-4539 (1983), Merck & Co., Inc., Rahway, N.J.
Folkman et al; Science 221:719-725 (1983).
Zucker-Franklin et al; Biochem. Biophys. Res. Commun. 126(1):540-3 (1985).
Ingber et al; Endocrinology 119(4):1768-1775 (Oct. 1986).
Chen et al; Lab. Invest. 59(4):453-459 (1988).
Chem. Abstracts (1985) 102:181218v.
DuBois et al. (1973) Biochem. and Biophys. Res. Comm. 50:1129-1135.
Chen Neil T.
Corey Elias J.
Folkman Moses J.
Carson Nancy S.
Griffin Ronald W.
President and Fellows of Harvard College
The Children's Medical Center Corporation
LandOfFree
Arylsulfatase inhibition and potentiation of angiostatic steroid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylsulfatase inhibition and potentiation of angiostatic steroid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfatase inhibition and potentiation of angiostatic steroid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1475962